EyePoint Pharmaceuticals (EYPT) Misses Q1 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Citi Opens 30-Day Upside Catalyst Watch on EyePoint Inc. (EYPT)
May 6, 2026 4:08 PM EDTCiti analyst Yigal Nochomovitz reiterated a Buy rating and $35.00 price target on EyePoint Inc. (NASDAQ: EYPT)
Opens 30-Day upside catalyst watch.For an analyst ratings summary and ratings history on EyePoint Inc. click here. For more ratings news on EyePoint Inc. click here.
Shares of EyePoint Inc. closed at $13.75 yesterday.
... More